Extend your visibility and reach through AAPP’s 2027 Virtual Industry Showcase Series. Virtual showcases are promotional activities that do not offer ACPE credit. From May through November, one showcase is available for each month listed below on a first-come, first-serve basis. AAPP offers a total of six showcase opportunities to our industry partners.
Alcohol and Depression, Anxiety, Bipolar and PTSD
No summary available
Pharmacist-led CMM visits, traditionally rooted in primary care, can be successfully integrated into specialty clinics to bolster health maintenance needs and resolve MTPs to help optimize therapies, while maintaining patient satisfaction rates. This model of pharmacy supports broader adoption of CMM within specialty care, offering potential benefits to patients, providers, and payers such as reduced health care costs, decreased provider administrative burden, and improved patient outcomes.
A 10-year review found that the VA's VIONE program resulted in more than 4.3 million potentially inappropriate medications being deprescribed among more than 1.5 million veterans. The VIONE program addresses polypharmacy by prompting clinicians to classify medications as vital, important, optional or not indicated and ensure every medication has an indication. The program has an estimated annualized cost avoidance of $479 million, and more than 29,000 clinicians have used it.
No summary available
This review is the clinical component of a three-part series to delineate how developmental translational neuroscience can inform and guide the development and implementation of treatments for adolescent substance use.
In decision analytical model expanding ASBI delivery in primary care was projected to reduce premature mortality and may represent an important strategy for improving population health.
AAPP submitted comments on CMS's CY 2027 Medicare Physician Fee Schedule proposed rule, supporting policies that strengthen integrated behavioral healthcare and expand access to psychiatric medication expertise. The letter endorses increased payment for the Psychiatric Collaborative Care Model (CoCM), supports permanent telehealth flexibilities, and encourages CMS to recognize psychiatric pharmacists as Medicare providers as it advances primary care payment reform.
No summary available
No summary available
Virtual Student Opportunities AAPP student members received FREE virtual registration to AAPP 2025! In-Person Student Opportunities For those who attended the event in Salt Lake City, Utah.
Evaluating Large Language Models in Response to Questions on Substance Use: Helpful or Harmful?
Understanding Recovery Capital and Transitions Out of Recovery Homes: Socio-Demographic Factors and Reported Reasons for Departure
Rethinking Punitive Responses to Underage Marijuana Use in the Era of Legalization: Insights from an Online Survey
People Seeking Treatment for Meth/Amphetamine Use Are Getting Older and Treatment Services Need to Adapt
Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial
No summary available
AAPP submitted comments supporting the DEA’s proposal to temporarily place concentrated 7-hydroxymitragynine (7-OH) products in Schedule I due to growing concerns about their opioid-like effects, including dependence, withdrawal, overdose, and other serious health risks. AAPP noted that these highly concentrated products are increasingly available online and in retail settings with limited oversight and often contain much higher levels of 7-OH than occur naturally in kratom.
In TRBD, adjunctive IV ketamine was well tolerated and associated with significant antidepressant effects.
Lower plasma iron and higher plasma selenium were each associated with greater dementia risk, identifying iron and selenium as potentially modifiable factors for dementia prevention, especially in selenium-replete populations.
No summary available
No summary available